Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: Impact of high on‐treatment platelet reactivity and diabetes mellitus status
- 19 March 2012
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 81 (1) , 42-49
Abstract
Background: In patients on dual antiplatelet therapy with aspirin and clopidogrel, the adjunctive use of cilostazol is associated with enhanced platelet inhibition. However, if cilostazol exerts different pharmacodynamic (PD) effects according to levels of on‐treatment platelet reactivity remains unknown. This study aimed to determine the PD effects of cilostazol in patients with and without high on‐clopidogrel platelet reactivity (HPR) according to diabetes mellitus (DM) status.Methods: This is a post‐hoc analysis derived from patients (n = 79) enrolled in a prospective, randomized, double‐blind, double‐dummy, crossover study comparing cilostazol with placebo in stable coronary artery disease patients on aspirin and clopidogrel therapy. In the present analysis, patients were divided according to the presence or absence of HPR (HPR and non‐HPR). HPR was defined as a P2Y12 units (PRU) > 240 as assessed by the VerifyNow P2Y12 assay. The PD effects of cilostazol were evaluated in patients with and without HPR according to DM status.Results: Significant absolute changes in PRU values were observed after adjunctive cilostazol in both HPR [53.4 (95% CI 24.7–82.1), P = 0.001] and non‐HPR [40.8 (95% CI 28.7–52.8), P < 0.0001] patients. This difference was statistically significant in HPR patients with DM (P = 0.001), but not without DM (P = 0.24), and in non‐HPR patients with and without DM (P = 0.0001 for both). The greatest mean reduction in PRU was observed in HPR patients with DM (72.9; 95% CI 33.7–112.0). Thrombin generation was not affected by cilostazol, irrespective of HPR status.Conclusion: Cilostazol reduces platelet reactivity both in HPR and non‐HPR patients, although these PD effects are enhanced in HPR patients with DM. Nevertheless, larger studies are needed to better evaluate possible differential effects of cilostazol on platelet reactivity by diabetes status.Keywords
This publication has 34 references indexed in Scilit:
- Optimizing Platelet Inhibition in Clopidogrel Poor MetabolizersJACC: Cardiovascular Interventions, 2011
- Multicenter Randomized Trial Evaluating the Efficacy of Cilostazol on Ischemic Vascular Complications After Drug-Eluting Stent Implantation for Coronary Heart DiseaseJACC, 2011
- Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapyThrombosis and Haemostasis, 2011
- Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine DiphosphateJACC, 2010
- Clopidogrel response variability: Current status and future directionsThrombosis and Haemostasis, 2009
- A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 studyEuropean Heart Journal, 2008
- Pharmacologic Approaches to Restenosis PreventionThe American Journal of Cardiology, 2007
- Effects of Triple Antiplatelet Therapy (Aspirin, Clopidogrel, and Cilostazol) on Platelet Aggregation and P-Selectin Expression in Patients Undergoing Coronary Artery Stent ImplantationThe American Journal of Cardiology, 2007
- Variability in Individual Responsiveness to ClopidogrelJACC, 2007
- Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleedingAtherosclerosis Supplements, 2005